Clinical Trial
doi: 10.1016/s0022-3476(83)80258-3.Trial of low doses of aspirin as prophylaxis in sickle cell disease
- PMID:6842340
- DOI: 10.1016/s0022-3476(83)80258-3
Item in Clipboard
Clinical Trial
Trial of low doses of aspirin as prophylaxis in sickle cell disease
J Greenberg et al. J Pediatr.1983 May.
Display options
Format
Display options
Format
Abstract
The effects of low doses of aspirin on the frequency and severity of painful vaso-occlusive crises were evaluated in children with sickle hemoglobinopathies. Aspirin was compared with placebo in 49 patients in a double-blind crossover study. Careful monitoring of patients revealed an average of 1.1 painful crises per patient year. During the 21 months of study, 70% of patients had a maximum of two painful crises, and 25% experienced four or more. The frequency and severity of crises were not affected by aspirin therapy. In view of aspirin's demonstrated effect on platelet function, we suggest that platelets do not contribute to the initiation or progression of the vaso-occlusive process.
Similar articles
- Design of the DOVE (Determining Effects of Platelet Inhibition on Vaso-Occlusive Events) trial: A global Phase 3 double-blind, randomized, placebo-controlled, multicenter study of the efficacy and safety of prasugrel in pediatric patients with sickle cell anemia utilizing a dose titration strategy.Hoppe CC, Styles L, Heath LE, Zhou C, Jakubowski JA, Winters KJ, Brown PB, Rees DC, Heeney MM.Hoppe CC, et al.Pediatr Blood Cancer. 2016 Feb;63(2):299-305. doi: 10.1002/pbc.25771. Epub 2015 Sep 24.Pediatr Blood Cancer. 2016.PMID:26402148Clinical Trial.
- A Multinational Trial of Prasugrel for Sickle Cell Vaso-Occlusive Events.Heeney MM, Hoppe CC, Abboud MR, Inusa B, Kanter J, Ogutu B, Brown PB, Heath LE, Jakubowski JA, Zhou C, Zamoryakhin D, Agbenyega T, Colombatti R, Hassab HM, Nduba VN, Oyieko JN, Robitaille N, Segbefia CI, Rees DC; DOVE Investigators.Heeney MM, et al.N Engl J Med. 2016 Feb 18;374(7):625-35. doi: 10.1056/NEJMoa1512021. Epub 2015 Dec 8.N Engl J Med. 2016.PMID:26644172Clinical Trial.
- Real-time dose adjustment using point-of-care platelet reactivity testing in a double-blind study of prasugrel in children with sickle cell anaemia.Jakubowski JA, Hoppe CC, Zhou C, Smith BE, Brown PB, Heath LE, Inusa B, Rees DC, Small DS, Gupta N, Yao S, Heeney M, Kanter J.Jakubowski JA, et al.Thromb Haemost. 2017 Feb 28;117(3):580-588. doi: 10.1160/TH16-09-0731. Epub 2016 Dec 8.Thromb Haemost. 2017.PMID:27929203Clinical Trial.
- Piracetam for reducing the incidence of painful sickle cell disease crises.Al Hajeri AA, Fedorowicz Z, Omran A, Tadmouri GO.Al Hajeri AA, et al.Cochrane Database Syst Rev. 2007 Apr 18;(2):CD006111. doi: 10.1002/14651858.CD006111.pub2.Cochrane Database Syst Rev. 2007.Update in:Cochrane Database Syst Rev. 2016 Feb 12;2:CD006111. doi: 10.1002/14651858.CD006111.pub3.PMID:17443614Updated.Review.
- Ketamine Infusion for Pain Control in Acute Pediatric Sickle Cell Painful Crises.Hagedorn JM, Monico EC.Hagedorn JM, et al.Pediatr Emerg Care. 2019 Jan;35(1):78-79. doi: 10.1097/PEC.0000000000000978.Pediatr Emerg Care. 2019.PMID:27902670Review.
Cited by
- Drug Therapies for the Management of Sickle Cell Disease.Rai P, Ataga KI.Rai P, et al.F1000Res. 2020 Jun 11;9:F1000 Faculty Rev-592. doi: 10.12688/f1000research.22433.1. eCollection 2020.F1000Res. 2020.PMID:32765834Free PMC article.Review.
- The Evolving Pharmacotherapeutic Landscape for the Treatment of Sickle Cell Disease.Ballas SK.Ballas SK.Mediterr J Hematol Infect Dis. 2020 Jan 1;12(1):e2020010. doi: 10.4084/MJHID.2020.010. eCollection 2020.Mediterr J Hematol Infect Dis. 2020.PMID:31934320Free PMC article.Review.
- A pilot study of eptifibatide for treatment of acute pain episodes in sickle cell disease.Desai PC, Brittain JE, Jones SK, McDonald A, Wilson DR, Dominik R, Key NS, Parise LV, Ataga KI.Desai PC, et al.Thromb Res. 2013 Sep;132(3):341-5. doi: 10.1016/j.thromres.2013.08.002. Epub 2013 Aug 8.Thromb Res. 2013.PMID:23973010Free PMC article.Clinical Trial.
- A phase 1 study of prasugrel in patients with sickle cell disease: pharmacokinetics and effects on ex vivo platelet reactivity.Jakubowski JA, Zhou C, Small DS, Winters KJ, Lachno DR, Frelinger AL 3rd, Howard J, Mant TG, Jurcevic S, Payne CD.Jakubowski JA, et al.Br J Clin Pharmacol. 2013 Jun;75(6):1433-44. doi: 10.1111/bcp.12042.Br J Clin Pharmacol. 2013.PMID:23171128Free PMC article.Clinical Trial.
- Genetic diminution of circulating prothrombin ameliorates multiorgan pathologies in sickle cell disease mice.Arumugam PI, Mullins ES, Shanmukhappa SK, Monia BP, Loberg A, Shaw MA, Rizvi T, Wansapura J, Degen JL, Malik P.Arumugam PI, et al.Blood. 2015 Oct 8;126(15):1844-55. doi: 10.1182/blood-2015-01-625707. Epub 2015 Aug 18.Blood. 2015.PMID:26286849Free PMC article.
Publication types
MeSH terms
Substances
Related information
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical